ANTIDIABETICOS ORALES PDF

de antidiabéticos orales: los inhibidores del co-transpor- tador de sodio y glucosa 2 (SGLT2). La dapagliflozina actúa como un inhibidor selectivo, reversible y. Aportaciones respecto a las otras familias de antidiabéticos orales. Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP- 4. Discover ideas about Diabetes. Clasificación de los antidiabéticos orales. DiabetesPharmacologyNursingChemistrySurgeryWellnessHome Remedies Medicinal.

Author: Vudomuro Madal
Country: Estonia
Language: English (Spanish)
Genre: Finance
Published (Last): 13 August 2009
Pages: 78
PDF File Size: 19.76 Mb
ePub File Size: 4.59 Mb
ISBN: 614-4-81453-341-9
Downloads: 4775
Price: Free* [*Free Regsitration Required]
Uploader: Darr

Antidiabeticos orales

Eficacia reductora A1c simil a SU. N Engl J Med,pp. Rc PPAR gamma, agonistas nucleares. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. See more popular or the latest antidiabeticoe. Creating downloadable prezi, be patient.

ANTIDIABETICOS ORALES PDF

Send the link below via email or IM. Efficacy and safety of the dipeptydil peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus inadequately controlled by glyburide monotherapy. Effect of Noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Curr Med Res Opin, 25pp. The efficacy and safety of saxagliptin when added to metformin antidiabeticso in patients with inadequately controlled type 2 diabetes with metformin alone.

  JANET MALCOLM EL PERIODISTA Y EL ASESINO PDF

ANTIDIABETICOS ORALES PDF

Effects of exenatide exendin-4 on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Metab Res Rev, 26pp.

A firewall is blocking access to Prezi content. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: Ciudad Universitaria Carrera 30 No Existen varios sistemas para administrar insulina, entre los que oraels encuentran: Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Glucagon like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression antudiabeticos increase cell mass in the pancreas of old glucose intolerant rats. Ann Intern Med,pp. However, these agents must continue to be evaluated in long-term studies performed in clinical practice to ensure their effectiveness and safety profile, as well as to determine their precise role among all the currently available options in the treatment of type 2 diabetes.

Antidiabeticos orales

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: Do you really want to delete this prezi? Systematic review and meta-analysis. Check out this article to learn more or contact your system administrator.

  DISPARADORES EN SQL SERVER PDF

Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: Efficacy and safety of incretin therapy in type 2 diabetes. Contributions with respect to other families of oral antidiabetic agents.

Aumento riesgo oralse vertebrales Aumento de IAM. Efficacy and safety of inhalated insulin therapy in adults with diabetes mellitus. Clin Ther, 28pp.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: Diabetes Care, 32pp. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. A role for glucagon peptide-1 in the central regulation of feeding.